Thyroid Cancer clinical trials in Virginia

5 actively recruiting thyroid cancer trials at 3 sites across Virginia.

Data from ClinicalTrials.gov · last refreshed 2026-11-09

Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.

NCT ID: NCT03093116

Sites in Virginia:

Local Institution - 2137 — Fairfax, Virginia

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier

NCT ID: NCT05786924

Sites in Virginia:

NEXT Virginia — Fairfax, Virginia

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.

Sponsor: M.D. Anderson Cancer Center

NCT ID: NCT06959511

Sites in Virginia:

University of Virginia — Charlottesville, Virginia

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

Sponsor: Pierre Fabre Medicament

NCT ID: NCT04913285

Sites in Virginia:

Virginia Cancer Specialists — Fairfax, Virginia

View on ClinicalTrials.gov →

NA Recruiting Academic/Other

Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer

The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment. The main questions it aims to answer are: - Does the decision aid help par…

Sponsor: Georgetown University

NCT ID: NCT06980103

Sites in Virginia:

Inova Health System — Falls Church, Virginia

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09